Prevalence of risk factors for carbapenem-resistant Klebsiella pneumoniae in hospitalized patients. Systematic review

Henry Mejía-Zambrano

doi:10.54034/mic.e1408

Authors

Henry Mejía-Zambrano Universidad Privada San Juan Bautista. Lima, Perú https://orcid.org/0000-0001-7325-7796

DOI:

https://doi.org/10.54034/mic.e1408

Keywords:

risk factors, Carbapenem-Resistant Klebsiella pneumoniae

Abstract

Introduction. The cases of infection for Carbapenem-Resistant Klebsiella pneumoniae (CRKP) have increased. The patients with infection for Carbapenem-Resistant Klebsiella pneumonia have a terrible forecast and a high mortality rate. Objective. We determine the prevalence of risk factors in patients hospitalized for CRKP. Methods. We perform a search bibliographic of the literature in Pub Med, MEDLINE, and SCOPUS, to December 13, 2021. This systematic review included observational studies on risk factors in patients hospitalized for CRKP. We evaluated the quality methodologic of articles on the base of the Newcastle Ottawa Scale (NOS) of nine stars. Results. we observed that the majority were male (62.90%), the average age was 61 years, and 883 patients with CRKP were counted from the different studies. The main risk factors for CRKP were previous hospitalizations (67.9%), previous use of carbapenems and ß-lactam/ß-lactamase inhibitor (49.59% and 45.49%, respectively), previous venous catheterization (44.99%) and previous stay in the intensive care unit (ICU) (42.9%). Conclusions. In this systematic review, we was the conclusion that the prevalence of risk factors of CRKP in patients hospitalized are previous hospitalizations, use last of antibiotics as carbapenems, ß-lactams/inhibitors, ß-lactamase, previous procedures as central venous catheterization and earlier stays in intensive care units (ICU). These findings can promote the prevention of CRKP infections and rational control over the use of antibiotics from the Ministry of Health towards the general population.

References

Wei-min Z, Zhe Y, Hong-yu Z. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection relative to two types of control patients: a systematic review and meta-analysis. Antimicrobial Resistance and Infection Control. 2020; 9(1): 23. Doi: 10.1186/S13756-020-0686-0

Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: A global multifaceted phenomenon. Pathogens and Global Health. 2015; 109(7): 309-318. Doi: 10.1179/2047773215Y.0000000030

Tzouvelekis L, Markogiannakis A, Psichogiou M, Tassios P, Daikos G. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: An evolving crisis of global dimensions. Clinical Microbiology Reviews. 2012; 25(4): 682-707. Doi: 10.1128/CMR.05035-11

Martirosov D, Lodise T. Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae. Diagnostic Microbiology and Infectious Disease. 2016; 85(2): 266-275. Doi: 10.1016/j.diagmicrobio.2015.10.008

Falagas M, Tansarli G, Karageorgopoulos D, Vardakas K. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerging Infectious Diseases. 2014; 20(7): 1170-1175. Doi: 10.3201/ eid2007.121004

Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: A new threat to our antibiotic armamentarium. Archives of Internal Medicine. 2005; 165(12): 1430-1435. Doi: 10.1001/archinte.165.12.1430

Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Annals of clinical microbiology and antimicrobials. 2017; 16(1). Doi: 10.1186/S12941-017-0191-3

Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumonia. Antimicrobial agents and chemotherapy. 2001; 45(4): 1151-1161. Doi: 10.1128/AAC.45.4.1151-1161.2001

Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2011; 53(11): 60-67. Doi: 10.1093/CID/CIR202

Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clinical Microbiology Reviews. 1998; 11(4): 589-603. Doi: 10.1128/CMR.11.4.589

Kwak YG, Choi S, Choo E, Chung J, Jeong J, Kim N, et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumonia among hospitalized patients. Microbial Drug Resistance. 2005; 11(2): 165-169. Doi: 10.1089/mdr.2005.11.165

Akgul F, Bozkurt I, Sunbul M, Esen S, Leblebicioglu H. Risk factors and mortality in the Carbapenem-resistant Klebsiella pneumonia infection: case-control study Pathogens and global health. 2016; 110(7-8): 321-325. Doi: 10.1080/20477724.2016.1254976

Mejía Zambrano H. Eficacia de la terapia con aminoglicósidos en infectados por Klelsiella pneumoniae resistente a carbapenémicos. REE. 2022; 16(3):92-105. Available: https://eugenioespejo.unach.edu.ec/index.php/EE/article/view/475

Liu P, Li X, Mei X, Xuan X, Kewen S, Shuai CH, et al. Risk Factors for Carbapenem-Resistant Klebsiella pneumoniae Infection: A Meta-Analysis. Microbial Drug Resistance. 2018; 24(2): 190-198. Doi: 10.1089/mdr.2017.0061

Urrútia G, Bonfill X. Declaración PRISMA: una propuesta para mejorar la publicación de revisiones sistemáticas y metaanálisis. Med Clin. 2010; 135(11): 507-511. Disponible: https://es.cochrane.org/sites/es.cochrane.org/files/public/uploads/PRISMA_Spanish.pdf

Wells GA, Shea B, O´Connell D, Peterson J, Welch V, Losos M, et al. he Newcastle-Ottawa Scale (NOS) para evaluar la calidad de los estudios no aleatorios en el metanálisis. Disponible en: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (consultado el 7/03/2022)

Hu Y, Liu C, Shen Z, Zhou H, Cao J, Chen S, et al. prevalence, risk factors and molecular epidemiology of carbapenem-resistant Klebsiella pneumonia in patients from Zhejiang, China, 2008–2018. Emerging Microbes and Infections. 2020; 9(1): 1771-1779. Doi: 10.1080/22221751.2020.1799721

Hsu JY, Chuang YC, Wang JT, Chen YC, Hsieh SM. Healthcare-associated carbapenem-resistant Klebsiella pneumoniae bloodstream infections: Risk factors, mortality, and antimicrobial susceptibility, 2017-2019. J Formos Med Assoc. 2021; 120(11): e1994-2002. Doi: 10.1016/J.JFMA.2021.04.014

Tian L, Tan R, Chen Y, Sun J, Liu J, Qu H, et al. Epidemiology of Klebsiella pneumoniae bloodstream infections in a teaching hospital: factors related to the carbapenem resistance and patient mortality. Antimicrobial resistance and infection control. 2016; 5(1): 48. Doi: 10.1186/S13756-016-0145-0

Büyüktuna SA, Hasbek M, Çelik C, Ünlüsavuran M, Avcı O, Baltacı S, et al. [Klebsiella pneumoniae Infections in the Intensive Care Unit: Risk Factors Related to Carbapenem Resistance and Patient Mortality]. Mikrobiyoloji bulteni. 2020; 54(3): 378-391. Doi: 10.5578/MB.69679.

Wang Z, Qin R, Huang L, Sun L, et al. Risk Factors for Carbapenem-resistant Klebsiella pneumoniae Infection and Mortality of Klebsiella pneumoniae Infection. Chinese Medical Journal. 2018; 131(1): 56. Doi: 10.4103/0366-6999.221267

Chang H, Wei J, Zhou W, Yan X, Cao X, Zuo L, et al. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014–2018: Clinical impact of carbapenem resistance in a large tertiary hospital of China. Journal of Infection and Public Health. 2020; 13(5): 784-790. Doi: 10.1016/j.jiph.2019.11.014

Xiao T, Zhu Y, Zhang S, Wang Y, Shen P, Zhou Y, et al. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients. The Journal of infectious diseases. 2020; 2021(2): 174-183. Doi: 10.1093/ INFDIS/JIZ559

Liu KS, Tong YS, Lee MT, Lin HY, Lu MC. Risk Factors of 30-Day All-Cause Mortality in Patients with Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infection. Journal of personalized medicine. 2021; 11(7): 616. Doi: 10.3390/JPM11070616

Li Y, Li J, Hu T, Hu J, Song N, Zhang Y, et al. Five-year change of prevalence and risk factors for infection and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary hospital in North China. Antimicrobial Resistance and Infection Control. 2020; 9(1): 79. Doi: 10.1186/S13756-020-00728-3

Zhang Y, Guo L, Song W, Wang Y, Dong F, Liu G. Risk factors for carbapenem-resistant K. pneumoniae bloodstream infection and predictors of mortality in Chinese pediatric patients. BMC infectious diseases. 2018; 18(1): 248. Doi: 10.1186/S12879-018-3160-3

Zhang G, Zhang M, Sun F, Zhou J, Wang Y, Zhu D, et al. Epidemiology, mortality and risk factors for patients with K. pneumoniae bloodstream infections: Clinical impact of carbapenem resistance in a tertiary university teaching hospital of Beijing. Journal of infection and public health. 2020; 13(11): 1710-1714. Doi: 10.1016/J.JIPH.2020.09.012

Zhang H, Wang J, Zhou W, Yang M, Wang R, Yan X, et al. Risk Factors and Prognosis of Carbapenem-Resistant Klebsiella pneumoniae Infections in Respiratory Intensive Care Unit: A Retrospective Study. Infection and drug resistance. 2021; 14: 3297-3305. Doi: 10.2147/IDR.S317233

Yuan Y, Wang J, Yao Z, Ma B, Li Y, Yan W, et al. Risk Factors for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections and Outcomes. Infection and drug resistance. 2020; 13: 207-215. Doi: 10.2147/IDR.S223243

Cienfuegos-Gallet A, Ocampo De Los Ríos A, Sierra Viana P, Ramirez Brinez F, Restrepo Castro C, Roncancio Villamil G, et al. Risk factors and survival of patients infected with carbapenem-resistant Klebsiella pneumoniae in a KPC endemic setting: a case-control and cohort study. BMC infectious diseases. 2019; 19(1): 830. Doi: 10.1186/S12879-019-4461-X

Centro Europeo para la Prevención y el Control de Enfermedades. Vigilancia de la resistencia a los antimicrobianos en Europa - Informe anual de la Red europea de vigilancia de la resistencia a los antimicrobianos (EARS-Net) 2019. Disponible: https://www.eca.europa.eu/Lists/ECADocuments/SR19_21/SR_Antimicrobial_resistance_ES.pdf